Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease

@inproceedings{Shoji2016Interleukin34AA,
  title={Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease},
  author={Hirotaka Shoji and Sachiyo Yoshio and Yohei Mano and Erina Kumagai and M Sugiyama and Masaaki Korenaga and Taeang Arai and Norio Itokawa and Masanori Atsukawa and Hiroshi Aikata and Hideyuki Hyogo and Kazuaki Chayama and Tomohiko Ohashi and Kiyoaki Ito and Masashi Yoneda and Yuichi Nozaki and Takumi Kawaguchi and Takuji Torimura and Masanori Abe and Yoichi Hiasa and Moto Fukai and Toshiya Kamiyama and Akinobu Taketomi and Masashi Mizokami and Tatsuya Kanto},
  booktitle={Scientific reports},
  year={2016}
}
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic non-viral liver disease. Activation of macrophages and hepatic stellate cells is a critical step that promotes liver fibrosis. We aimed to explore the feasibility of interleukin-34 (IL-34), a key regulator of macrophages, as a fibrosis marker in patients with NAFLD. We enrolled 197 liver biopsy-proven NAFLD patients. We evaluated the serum levels of IL-34, macrophage-colony stimulating factor (M-CSF), soluble CD163 (sCD163… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 10 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

miR - 28 – 5 pIL - 34 - Macrophage Feedback Loop Modulates Hepatocellular Carcinoma Metastasis

S. L. Zhou
Hepatology • 2016

IL-34 is associated with obesity, chronic inflammation, and insulin resistance.

The Journal of clinical endocrinology and metabolism • 2014

Similar Papers

Loading similar papers…